Breast Cancer Study

To get critical insights from Medical/Clinical Oncologists and Gynecologic Oncologists to better understand how the treatment of HR+/HER2- and Triple Negative Breast Cancer (TNBC) patients are managed.
To know the overall treatment strategy and protocol followed for HR+/HER- and Triple Negative Breast Cancer (TNBC) across all the target markets. In addition, the broad line objectives included:
1. Pros and cons of current treatment options
2. Treatment gaps and unmet medical needs
3. Patient charts for both subtypes HR+/HER- and TNBC

More Services

We conducted a quantitative primary research targeting Medical Oncologists and Gynecologic Oncologists with 3 to 30 years of experience, devoting over 60% of their time to direct patient care and responsible for the decision to initiate drug therapy for HR+/Her2- and TNBC.
Length of Interview: 35 minutes.
Target Markets: Romania, Serbia, Bulgaria, Croatia, Slovenia and Hungary.
Questions pivoted across the following areas:
1. Patient Journey and Demographics: Average patient count for both sub-type, split between Stage-0,I,II,III,IV/metastatic for HR+/HER2- and TNBC, first diagnosis to treatment, germline BRCA mutation status.
2. Treatment strategy and protocol: All lines of treatment, prescription percentage for all drug classes, advantages and disadvantages of various treatment options for these patients.
We deployed a specialist team of healthcare researchers, comprised of experienced Research analysts with skillsets for oncology study discussion with specialists and project managers with experience in data analysis.

More Services

This aided the client in creating the report on current patient demographics, specifically for HR+/Her2- and TNBC patient subtype.
Our assistance helped the client generate actionable insights in optimizing their breast cancer product pipeline and realign their product strategy.
Data was delivered in SPSS and Excel format

More Services

Let's Connect